viewCytoDyn Inc.

Full interview: CytoDyn reveals adjustment to its HIV monotherapy treatment in 'major' announcement

CytoDyn Inc (OTCMKTS:CYDY) CEO Dr Nader Pourhassan tells Proactive that the firm’s Senior Science Advisor Dr. Jonah Sacha, who leads the development of leronlimab (PRO 140) as a potential therapeutic for HIV Pre-Exposure Prophylaxis (PrEP) and HIV, has 'tweaked' the product in-vitro to produce a therapy that would be injected only once per month.

Dr Pourhassan says the move comes with the biotech competing against the big pharma majors like Gilead Sciences and ViiV Healthcare, which have each revealed progression in their own therapies to treat HIV.

Quick facts: CytoDyn Inc.

Price: 1.17 USD

Market: OTCQB
Market Cap: $503.98 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...



Xpediator's Stephen Blyth outlines five-year growth plans as core businesses...

Xpediator PLC's (LON:XPD) Stephen Blyth speaks to Proactive London following the release of its 2019 trading update. The firm saw turnover rise 19% to £212mln - boosted by acquisitions and organic growth while adjusted pre-tax profit's expected to be slightly above £5mln. Blyth says a big...

2 days, 14 hours ago

2 min read